<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>Shahed University</PublisherName>
				<JournalTitle>Daneshvar Medicine</JournalTitle>
				<Issn>2716-9723</Issn>
				<Volume>19</Volume>
				<Issue>4</Issue>
				<PubDate PubStatus="epublish">
					<Year>2020</Year>
					<Month>09</Month>
					<Day>26</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Synthesis of chimeric T cell receptor with OX40 co-stimulatory receptor targeted against breast cancer cells</ArticleTitle>
<VernacularTitle>Synthesis of chimeric T cell receptor with OX40 co-stimulatory receptor targeted against breast cancer cells</VernacularTitle>
			<FirstPage>1</FirstPage>
			<LastPage>8</LastPage>
			<ELocationID EIdType="pii">1479</ELocationID>
			
			
			<Language>FA</Language>
<AuthorList>
<Author>
					<FirstName>Sepideh</FirstName>
					<LastName>Khaleghi</LastName>
<Affiliation></Affiliation>

</Author>
<Author>
					<FirstName>Fatemeh</FirstName>
					<LastName>Rahbarizadeh</LastName>
<Affiliation></Affiliation>

</Author>
<Author>
					<FirstName>Keyhan</FirstName>
					<LastName>Azadmanesh</LastName>
<Affiliation></Affiliation>

</Author>
<Author>
					<FirstName>Mohammad Javad</FirstName>
					<LastName>Rasaiee</LastName>
<Affiliation></Affiliation>

</Author>
<Author>
					<FirstName>Farnoush</FirstName>
					<LastName>Jafari</LastName>
<Affiliation></Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2020</Year>
					<Month>09</Month>
					<Day>26</Day>
				</PubDate>
			</History>
		<Abstract>Background and Objective: Chimeric antigen T cell receptors provide a good approach for adoptive immunotherapy of cancer. In this new kind of chimeric T cell receptor, nanobodies are replaced as variable fragment of T cell receptor. Nanobodies (VHH) are the smallest fragments of antibodies that have great homology to human VH and low immunogenic potential. VHH-hing-CD28-CD3و construct was made in our laboratory. Tumor cells rarely provide costimulatory signals and hence CAR receptors that transmit just a CD3و signal can only initiate target cell killing and interferon γ release and fail to induce full activation. Although incorporation of a CD28 component results in IL-2 (Interlukin 2) release and limited proliferation, T cell activation remains incomplete. To optimize CAR signaling, tripartite endodomains were constructed which consist of CD28-OX40-CD3ζ. During T cell activation, OX40 transmits a potent and prolonged T cell activation signal and it is crucial for maintaining an immunological response. Materials and Methods: We designed overlapping primers that contain 60% of OX40 sequence, then, CD28-Ox40-CD3ζ region was synthesized by SOE-PCR, consequently, it was replaced with CD28-CD3ζ region in VHH-Hing-CD28-CD3ζ construct. Then, this construct was transfected in Jurkat T cells, so IL-2 secretion and T cells proliferation were increased. Results: CD28-OX40-CD3ζ tripartite cytoplasmic domain provided a full complement of activation, proliferation, and survival signals for enhanced anti-tumor activity. Conclusion: With IL-2 and semi-quantitative RT PCR, it is concluded that mRNA expression of pCDNA-1-hinge-CAR-OX40 and pCDNA-2-hinge-CAR-OX40 constructs are the same but the function of pCDNA-2-hinge-CAR-OX40 construct is more than the others.</Abstract>
			<OtherAbstract Language="FA">Background and Objective: Chimeric antigen T cell receptors provide a good approach for adoptive immunotherapy of cancer. In this new kind of chimeric T cell receptor, nanobodies are replaced as variable fragment of T cell receptor. Nanobodies (VHH) are the smallest fragments of antibodies that have great homology to human VH and low immunogenic potential. VHH-hing-CD28-CD3و construct was made in our laboratory. Tumor cells rarely provide costimulatory signals and hence CAR receptors that transmit just a CD3و signal can only initiate target cell killing and interferon γ release and fail to induce full activation. Although incorporation of a CD28 component results in IL-2 (Interlukin 2) release and limited proliferation, T cell activation remains incomplete. To optimize CAR signaling, tripartite endodomains were constructed which consist of CD28-OX40-CD3ζ. During T cell activation, OX40 transmits a potent and prolonged T cell activation signal and it is crucial for maintaining an immunological response. Materials and Methods: We designed overlapping primers that contain 60% of OX40 sequence, then, CD28-Ox40-CD3ζ region was synthesized by SOE-PCR, consequently, it was replaced with CD28-CD3ζ region in VHH-Hing-CD28-CD3ζ construct. Then, this construct was transfected in Jurkat T cells, so IL-2 secretion and T cells proliferation were increased. Results: CD28-OX40-CD3ζ tripartite cytoplasmic domain provided a full complement of activation, proliferation, and survival signals for enhanced anti-tumor activity. Conclusion: With IL-2 and semi-quantitative RT PCR, it is concluded that mRNA expression of pCDNA-1-hinge-CAR-OX40 and pCDNA-2-hinge-CAR-OX40 constructs are the same but the function of pCDNA-2-hinge-CAR-OX40 construct is more than the others.</OtherAbstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">chimeric T cell receptor</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Nanobody</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">OX40</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">T lymphocyte</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://daneshvarmed.shahed.ac.ir/article_1479_bbf4b9d152feab0487d2aef03be5f2aa.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
